Aspergillus susceptibility testing in patients with cancer and invasive aspergillosis: difficulties in establishing correlation between in vitro susceptibility data and the outcome of initial amphotericin B therapy.
about
Susceptibility breakpoints for amphotericin B and Aspergillus species in an in vitro pharmacokinetic-pharmacodynamic model simulating free-drug concentrations in human serum.Drosophila melanogaster as a model organism for invasive aspergillosis.Regulatory circuitry governing fungal development, drug resistance, and disease.Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic modelSingle-dose pharmacodynamics of amphotericin B against Aspergillus species in an in vitro pharmacokinetic/pharmacodynamic model.Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistanceWhen primary antifungal therapy fails.Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network.Antifungal Resistance: An Emerging Reality and A Global Challenge.Comparison of disk diffusion, E-test and broth microdilution test in determination of susceptibility of Aspergillus species to amphotericin B, itraconazole and voriconazole.Amphotericin B in vitro resistance is associated with fatal Aspergillus flavus infection.
P2860
Q33622932-D0315358-F0B0-4FF2-AB31-77C2EB1AC7CFQ33709967-3CADB181-C01C-4DBC-B653-1985DC1FEEBDQ34190284-D4A55DBB-D476-4023-B122-5A4F7F077574Q35666627-C1C2CFB3-BB14-4F07-BE74-FF6D92D2A583Q37036445-DD4C316A-9730-4EBD-A27B-F1DFE43FE2E9Q37122826-C10299CA-43C9-4C9D-BF26-755552014816Q37141191-031B680C-390F-4645-9C22-25C349063239Q37374804-1091800C-CE62-45F9-B325-9E21D3DA934FQ40040795-17BF89A9-CA55-4DD2-8FED-E0C14BD3B889Q43815790-B5881DA5-647F-4100-B326-BF6575C9C1DCQ51367866-9CC27866-E6FE-494A-8622-276CC0A3EC61
P2860
Aspergillus susceptibility testing in patients with cancer and invasive aspergillosis: difficulties in establishing correlation between in vitro susceptibility data and the outcome of initial amphotericin B therapy.
description
2005 nî lūn-bûn
@nan
2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Aspergillus susceptibility tes ...... nitial amphotericin B therapy.
@ast
Aspergillus susceptibility tes ...... nitial amphotericin B therapy.
@en
type
label
Aspergillus susceptibility tes ...... nitial amphotericin B therapy.
@ast
Aspergillus susceptibility tes ...... nitial amphotericin B therapy.
@en
prefLabel
Aspergillus susceptibility tes ...... nitial amphotericin B therapy.
@ast
Aspergillus susceptibility tes ...... nitial amphotericin B therapy.
@en
P2093
P2860
P1433
P1476
Aspergillus susceptibility tes ...... nitial amphotericin B therapy.
@en
P2093
Dimitrios P Kontoyiannis
Georgios Chamilos
Michail S Lionakis
Russell E Lewis
P2860
P304
P356
10.1592/PHCO.2005.25.9.1174
P407
P577
2005-09-01T00:00:00Z